Skip to main content
Evidence Snapshot

Wee1-like protein kinase

CHEMBL5491 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5491
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Wee1-like protein kinase as ChEMBL target CHEMBL5491, mapped to UniProt P30291. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Wee1-like protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5491
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30291
Wee1-like protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Wee1-like protein kinase matters

As of 2026-09-13

Wee1-like protein kinase is reviewed as Wee1-like protein kinase (UniProt P30291); Wee1-like protein kinase shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 1772 compounds, and 289 assays, with lead potency reaching pChEMBL 10.0.

Disease context
neoplasm

Wee1-like protein kinase shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ADAVOSERTIB, AZENOSERTIB.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include ADAVOSERTIB, AZENOSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 1772 compounds, and 289 assays for this target. The dominant activity type is IC50. CHEMBL5933715 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5933715 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Wee1-like protein kinase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30291, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1772
Total Compounds
289
Total Assays
8
Approved Drugs
IC50: 1531.0, KI: 73.0, EC50: 112.0, KD: 379.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5933715
 10.0 IC50 —
No preferred name
CHEMBL5876377
 10.0 IC50 —
No preferred name
CHEMBL5831450
 10.0 IC50 —
No preferred name
CHEMBL5278196
 10.0 IC50 —
No preferred name
CHEMBL4441166
 9.7 Ki —

Approved Drugs

Structure Compound First Approval
TOVORAFENIB
CHEMBL3348923
 2024
FEDRATINIB
CHEMBL1287853
 2019
BOSUTINIB
CHEMBL288441
 2012
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5491